Despite the setbacks of muraglitazar, tesaglitazar, and aleglitazar, the development of dual- and pan-PPAR agonists in metabolic diseases is gradually gaining momentum, as exemplified by chiglitazar (for T2DM), saroglitazar (for dyslipidemia), and elafibronor (for dyslipidemia). The gene discussed is PPARA; the disease is metabolic disease.